Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYNTOCINON vs PITOCIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Synthetic oxytocin binds to oxytocin receptors in the myometrium, causing increased intracellular calcium and uterine smooth muscle contraction. Also acts on mammary gland myoepithelium for milk ejection.
Oxytocin receptor agonist; stimulates uterine smooth muscle contractions and myoepithelial cell contraction in the mammary gland.
Induction or augmentation of labor,Facilitation of abortion in the second trimester,Postpartum hemorrhage prevention and treatment
Induction of labor,Augmentation of labor,Postpartum hemorrhage,Incomplete abortion,Uterine atony
10 units (1 m L) intravenously as a single dose after delivery; continuous infusion: 20 units in 1 L of normal saline or lactated Ringer's solution at 2-10 m U/min (0.1-0.5 m L/min) titrated to uterine response.
IV infusion: 0.5-2 m U/min, increase by 1-2 m U/min every 15-60 minutes until contractions are established; maximum 20 m U/min.
Terminal elimination half-life: 1–6 minutes (intravenous); 1–9 minutes (intramuscular). Clinically, effects dissipate rapidly after infusion cessation.
Terminal elimination half-life is 3-5 minutes (plasma) with a terminal half-life of 1-6 minutes for exogenously administered oxytocin; clinical effects persist 20-30 minutes due to receptor binding.
Rapidly metabolized in the liver and kidneys by oxytocinase (cysteine aminopeptidase) and other peptidases.
Primarily metabolized in the liver and kidneys by oxytocinase; also degraded in the gastrointestinal tract and by the lungs.
Renal: >99% as intact oxytocin; biliary/fecal: negligible (<1%).
Primarily renal: 90-95% of the dose is excreted in urine as intact peptide and metabolites; <1% excreted in feces via bile.
Low (~30%); primarily binds to albumin and oxytocin-specific carrier proteins (e.g., neurophysin I).
Approximately 30%, bound primarily to serum albumin and oxytocin-specific binding proteins.
0.2–0.3 L/kg; reflects limited distribution into extracellular fluid and minimal tissue binding.
0.3 L/kg (total body water distribution; higher in pregnancy). Clinical meaning: reflects distribution to peripheral tissues and uterus.
Intramuscular: ~20–40% (due to rapid enzymatic degradation); Intravenous: 100%.
Intramuscular: approximately 50-80% due to first-pass metabolism; Intravenous: 100%; Oral: negligible (<1%) due to rapid peptidase degradation.
No dosage adjustment required for renal impairment; oxytocin is rapidly metabolized and renally excreted, but no specific GFR-based guidelines exist.
No specific dose adjustment required; monitor for fluid overload.
No dosage adjustment required for hepatic impairment; oxytocin is metabolized primarily by the liver, but no Child-Pugh based modifications have been established.
No specific dose adjustment required.
Not indicated for pediatric use; safety and efficacy in children have not been established.
Not indicated for pediatric use.
Use with caution in elderly patients due to potential for uterine hyperstimulation and adverse cardiovascular effects; no specific dosage adjustments recommended.
Use lowest effective dose; monitor for fluid overload and hypertension.
NOT FOR ELECTIVE INDUCTION OF LABOR AT TERM DUE TO RISK OF UTERINE HYPERSTIMULATION, UTERINE RUPTURE, AND FETAL DISTRESS. SHOULD ONLY BE USED UNDER CONTINUOUS MEDICAL SUPERVISION WITH FETAL AND UTERINE MONITORING.
Only for use in hospital settings with adequate personnel and equipment. High doses or prolonged use may cause uterine hyperstimulation, tetanic contractions, or uterine rupture. Risk of water intoxication and hyponatremia due to antidiuretic effect.
Uterine hyperstimulation and tetany,Uterine rupture, especially in grand multipara or with prior cesarean,Water intoxication and hyponatremia due to antidiuretic effect (high doses),Fetal bradycardia, hypoxia, and neonatal jaundice,Hypotension and tachycardia with rapid IV administration
Monitor uterine activity and fetal heart rate continuously. Use cautiously in grand multiparity, cervical trauma, or overdistended uterus. Avoid simultaneous IV administration of fluids containing electrolytes in large volumes to minimize water intoxication.
Hypersensitivity to oxytocin or any component,Cephalopelvic disproportion,Fetal distress where delivery is not imminent,Prolapsed umbilical cord,Placenta previa,Vasa previa,Contraindicated for elective induction in term pregnancies
Hypersensitivity to oxytocin; significant cephalopelvic disproportion; unfavorable fetal presentation; fetal distress; hypertonic or hyperactive uterine patterns; contraindication to vaginal delivery; severe toxemia; invasive cervical cancer; previous uterine surgery (relative).
No food interactions are known. However, because oxytocin can cause water retention, advise moderate sodium intake to reduce risk of hyponatremia. No specific dietary restrictions.
No known food interactions. Maintain hydration and light diet as tolerated during labor.
Syntocinon (oxytocin) is not associated with teratogenic effects when used at standard doses for labor induction. However, prolonged high-dose exposure may cause fetal hypoxia, bradycardia, and neonatal hyperbilirubinemia. No trimester-specific malformation risk is established; uterine hyperstimulation risk is greatest during second and third trimester use.
Pitocin (oxytocin) is not associated with structural teratogenicity when used at therapeutic doses. However, prolonged high-dose exposure during labor may cause fetal distress, neonatal hyperbilirubinemia, and transient hyponatremia. In first trimester, no evidence of increased malformation risk. In second and third trimesters, use may induce uterine hyperstimulation leading to fetal hypoxia or uterine rupture. Risk is dose- and duration-dependent.
Oxytocin is endogenous in breast milk; exogenous administration does not significantly increase milk levels. M/P ratio not clinically relevant due to rapid metabolism. Considered compatible with breastfeeding.
Oxytocin is rapidly metabolized in maternal plasma and gastrointestinal tract; negligible amounts enter breast milk. Estimated infant dose is <1% of maternal therapeutic dose. No adverse effects reported in breastfed infants. M/P ratio not established; oxytocin is not measurable in milk after IV administration.
No standard dose adjustment required due to pregnancy-induced pharmacokinetic changes. However, uterine sensitivity to oxytocin increases with gestational age; lower starting doses may be used near term to avoid hyperstimulation.
No dose adjustment required for pharmacokinetic changes of oxytocin itself in pregnancy. However, pregnancy alters sensitivity to oxytocin: the uterus becomes more responsive with advancing gestation. Initiate at low dose (0.5–2 m U/min) and titrate based on uterine response, not standard weight-based dosing. No evidence of significant pharmacokinetic changes in clearance or volume of distribution altering dose requirements.
Syntocinon (oxytocin) is used for induction or augmentation of labor. Administer via controlled IV infusion using an infusion pump. Start at 0.5-2 m U/min and titrate every 30-60 min to achieve adequate contractions (3-5 per 10 min). Monitor for uterine hyperstimulation, fetal distress, or water intoxication (antidiuretic effect). Have magnesium sulfate, terbutaline, or other tocolytics available for hyperstimulation. Do not use if contraindicated (e.g., cephalopelvic disproportion, fetal distress, placenta previa).
Pitocin (oxytocin) is used for induction/augmentation of labor. Must be administered via IV infusion with strict monitoring of uterine activity and fetal heart rate. Titrate dose every 30-60 minutes. Maximum dose is typically 20 m U/min; higher doses increase risk of uterine hyperstimulation. Have terbutaline or magnesium sulfate available for tocolysis if needed. Avoid in cases of placental previa, vasa previa, or fetal distress. Use with caution in grand multiparity (≥5) due to risk of uterine rupture.
Syntocinon is given intravenously to start or strengthen labor contractions.,You will be closely monitored with an electronic fetal monitor.,Report any excessively frequent or prolonged contractions or severe pain immediately.,It may increase the risk of postpartum hemorrhage; staff is prepared to manage it.,Tell your healthcare provider about any history of heart disease or high blood pressure.
This medication induces contractions to start or strengthen labor.,You will be closely monitored throughout infusion for your and your baby's safety.,Report any severe or continuous abdominal pain, changes in fetal movement, or excessive bleeding.,You may feel stronger, more frequent contractions than natural labor.,Inform your healthcare provider of any allergies or previous uterine surgery.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYNTOCINON vs PITOCIN, answered by our medical review team.
SYNTOCINON is a Oxytocic that works by Synthetic oxytocin binds to oxytocin receptors in the myometrium, causing increased intracellular calcium and uterine smooth muscle contraction. Also acts on mammary gland myoepithelium for milk ejection.. PITOCIN is a Oxytocic that works by Oxytocin receptor agonist; stimulates uterine smooth muscle contractions and myoepithelial cell contraction in the mammary gland.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYNTOCINON and PITOCIN depend on the specific clinical indication. These are both Oxytocic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYNTOCINON is: 10 units (1 m L) intravenously as a single dose after delivery; continuous infusion: 20 units in 1 L of normal saline or lactated Ringer's solution at 2-10 m U/min (0.1-0.5 m L/min) titrated to uterine response.. The standard adult dose of PITOCIN is: IV infusion: 0.5-2 m U/min, increase by 1-2 m U/min every 15-60 minutes until contractions are established; maximum 20 m U/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYNTOCINON and PITOCIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYNTOCINON is classified as Category C. Syntocinon (oxytocin) is not associated with teratogenic effects when used at standard doses for labor induction. However, prolonged high-dose exposure may cause fetal hypoxia, bra. PITOCIN is classified as Category C. Pitocin (oxytocin) is not associated with structural teratogenicity when used at therapeutic doses. However, prolonged high-dose exposure during labor may cause fetal distress, neo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.